Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Long Term Follow Up of Patients with Stroke after SARS-CoV-2 infection and Incidence of Neurological Post-Acute Sequelae of COVID-19
Cerebrovascular Disease and Interventional Neurology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
6-006

Having a stroke after COVID-19 is associated with poorer long-term outcomes.


To explore symptoms of neurological post-acute sequelae of COVID-19 (PASC) in patients who developed stroke after SARS-CoV-2 infection.


SARS-CoV-2 infected inpatients who had a stroke were collected and retrospectively studied for presence of neurological PASC symptoms, 4 weeks to up to 1 year after their first inpatient admission with SARS-CoV-2 infection. All demographic, nominal and inpatient data including length of stay, discharge, medications, and lab data were compared.


57 patients with stroke after SARS-CoV-2 infection and 418 patients with SARS-CoV-2 infection who did not have a stroke were followed up to 1 year after initial admission with SARS-CoV-2 infection . Of these, 38 stroke COVID-19 patients (67%) and 233 non-stroke COVID-19 patients (58%) followed up or were readmitted to the hospital. There was a significant difference in age for stroke vs non-stroke cohorts (65.4±12.8 9 vs 51.0±18.2 p<0.0001). For stroke vs non-stroke patients, numbness (18.4% vs 11.6%), paresthesias (15.8% vs 8.5%), brain fog or cognitive impairment (7.8% vs 7.3%), weakness (21.1% vs 26.6%), fatigue (18.4% vs 32.6%), headaches (13.2% vs 17.6%), changes in smell of taste (5.3% vs 14.1%), sleep issues or insomnia (2.6% or 10.3%), and anxiety or depression (7.9% vs 20.6%) were reported. There was no significant difference in the incidence of neurological PASC symptoms between the two cohorts p>0.05 for all symptoms.


This preliminary analysis of COVID-19 patients with 1 year follow-up demonstrates that the incidence of neurological symptoms of PASC in stroke vs non-stroke COVID-19 patients differed but did not reach significance. Stroke is associated with long term symptoms which may be similar in nature, and can be exacerbated by neurological PASC. Work is in progress expanding the study size, enrolling more patients and confounding for concomitant neurological conditions.


Authors/Disclosures
Anam Khalid Shaikh (New Jersey Medical School)
PRESENTER
Miss Shaikh has nothing to disclose.
Mustafa Jaffry Mr. Jaffry has nothing to disclose.
Ronak Uday Trivedi Mr. Trivedi has nothing to disclose.
Kranthi Kiran Mandava Mr. Mandava has nothing to disclose.
Kazim Jaffry Mr. Jaffry has nothing to disclose.
Muhammed Ors Mr. Ors has nothing to disclose.
Iqra *Use 379943 Faiz, Masters student Ms. Faiz has nothing to disclose.
Firas Gerges (New Jersey Institute of Technology) Mr. Gerges has nothing to disclose.
Michel Boufadel (New Jersey Institute of Technology) Prof. Boufadel has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS) Dr. Souayah has received publishing royalties from a publication relating to health care.